A NEW HORMONAL-THERAPY FOR PROSTATIC-CANCER - LONG-TERM CLINICAL AND HORMONAL RESPONSE

被引:11
作者
AHMED, SR
GRANT, JBF
SHALET, SM
HOWELL, A
COSTELLO, CB
WEATHERSON, T
BLACKLOCK, NJ
机构
[1] CHRISTIE HOSP & HOLT RADIUM INST,DEPT ENDOCRINOL,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND
[2] CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND
[3] WITHINGTON HOSP,DEPT UROL,MANCHESTER M20 8LR,LANCS,ENGLAND
来源
BRITISH JOURNAL OF UROLOGY | 1986年 / 58卷 / 05期
关键词
D O I
10.1111/j.1464-410X.1986.tb05462.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:534 / 538
页数:5
相关论文
共 22 条
[1]   PRELIMINARY-REPORT ON USE OF DEPOT FORMULATION OF LHRH ANALOG ICI 118630 (ZOLADEX) IN PATIENTS WITH PROSTATIC-CANCER [J].
AHMED, SR ;
GRANT, J ;
SHALET, SM ;
HOWELL, A ;
CHOWDHURY, SD ;
WEATHERSON, T ;
BLACKLOCK, NJ .
BRITISH MEDICAL JOURNAL, 1985, 290 (6463) :185-187
[2]  
AHMED SR, 1983, LANCET, V2, P415
[3]   ADVANCED-CARCINOMA OF THE PROSTATE - TREATMENT WITH A GONADOTROPIN-RELEASING HORMONE AGONIST [J].
ALLEN, JM ;
OSHEA, JP ;
MASHITER, K ;
WILLIAMS, G ;
BLOOM, SR .
BMJ-BRITISH MEDICAL JOURNAL, 1983, 286 (6378) :1607-1609
[4]  
BERQUIST C, 1979, LANCET, V2, P215
[5]  
BERQUIST C, 1979, ACTA ENDOCRINOL-COP, V91, P601
[6]  
GELLER J, 1978, Urology, V12, P537, DOI 10.1016/0090-4295(78)90467-3
[7]  
GELLER J, 1968, SURG GYNECOL OBSTETR, V127, P748
[8]   Studies on prostatic cancer III The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate [J].
Huggins, C ;
Scott, WW ;
Hodges, CV .
JOURNAL OF UROLOGY, 1941, 46 (05) :997-1006
[9]   FAILURE OF LONG-TERM LUTEINIZING-HORMONE RELEASING HORMONE-TREATMENT FOR PROSTATIC-CANCER TO SUPPRESS SERUM LUTEINIZING-HORMONE AND TESTOSTERONE [J].
KERLE, D ;
WILLIAMS, G ;
WARE, H ;
BLOOM, SR .
BRITISH MEDICAL JOURNAL, 1984, 289 (6443) :468-469
[10]   THE INFLUENCE OF HORMONAL-THERAPY ON SURVIVAL OF MEN WITH ADVANCED PROSTATIC-CANCER [J].
LEPOR, H ;
ROSS, A ;
WALSH, PC .
JOURNAL OF UROLOGY, 1982, 128 (02) :335-340